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Abstract
Background: To determine the correlation between the optic nerve head (ONH) circulation determined by laser
speckle flowgraphy and the best-corrected visual acuity or retinal sensitivity before and after intravitreal bevacizumab
or ranibizumab for central retinal vein occlusion.
Methods: Thirty-one eyes of 31 patients were treated with intravitreal bevacizumab or ranibizumab for macular edema
due to a central retinal vein occlusion. The blood flow in the large vessels on the ONH, the best-corrected visual acuity,
and retinal sensitivity were measured at the baseline, and at 1, 3, and 6 months after treatment. The arteriovenous
passage time on fluorescein angiography was determined. The venous tortuosity index was calculated on color fundus
photograph by dividing the length of the tortuous retinal vein by the chord length of the same segment. The blood
flow was represented by the mean blur rate (MBR) determined by laser speckle flowgraphy. To exclude the influence
of systemic circulation and blood flow in the ONH tissue, the corrected MBR was calculated as MBR of ONH vessel
area – MBR of ONH tissue area in the affected eye divided by the vascular MBR – tissue MBR in the unaffected eye.
Pearson’s correlation tests were used to determine the significance of correlations between the MBR and the
best-corrected visual acuity, retinal sensitivity, arteriovenous passage time, or venous tortuosity index.
Results: At the baseline, the corrected MBR was significantly correlated with the arteriovenous passage time and venous
tortuosity index (r = -0.807, P < 0.001; r = -0.716, P < 0.001; respectively). The corrected MBR was significantly correlated
with the best-corrected visual acuity and retinal sensitivity at the baseline, and at 1, 3, and 6 months (all P < 0.050). The
corrected MBR at the baseline was significantly correlated with the best-corrected visual acuity at 6 months (r = -0.651,
P < 0.001) and retinal sensitivity at 6 months (r = 0.485, P = 0.005).
Conclusions: The pre-treatment blood flow velocity of ONH can be used as a predictive factor for the best-corrected
visual acuity and retinal sensitivity after anti-VEGF therapy for central retinal vein occlusion.
Trial registration: Trial Registration number: UMIN000009072. Date of registration: 10/15/2012.
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Background
A central retinal vein occlusion (CRVO) is one of the
major causes of vision reduction, and anti-vascular
endothelial growth factor (VEGF) agents have been
shown to significantly improve visual acuity in eyes with
macular edema (ME) due to a CRVO [1].
Laser speckle flowgraphy (LSFG) is a non-invasive
method of real-time measurements of the blood flow on
the optic nerve head (ONH), retina, and choroid [2–6].
It can measure the relative blood flow velocity, called
the mean blur rate (MBR), that has been shown to be
significantly correlated with the actual blood flow rate
determined by the hydrogen gas clearance method and
the microspheres technique [7, 8]. It has been reported
that LSFG can record the blood flow from the same
location of an eye with high reproducibility especially on
the ONH [9]. This then provides an accurate way to
monitor the circulation changes before and after phar-
macological interventions [10].
Yamada et al. reported that the MBR values in large
ONH vessels measured by LSFG were correlated with
the higher aqueous VEGF concentrations in eyes with
CRVO [11]. Nagaoka et al. reported that a single intra-
vitreal bevacizumab (IVB) injection did not affected the
retinal microcirculation in eyes with acute branch retinal
vein occlusion (BRVO) for at least 3 months after the in-
jection [12]. However, there has been no report that
compared the ocular circulation before and after anti-
VEGF therapy for CRVO except for a report of 3 cases
in which the statistical association between ONH circu-
lation and visual function was not determined [13].
Thus, the purpose of this study was to examine the
relationship between the retinal blood flow and visual
acuity or retinal sensitivity in 31 eyes before and after
IVB or intravitreal ranibizumab (IVR) for CRVO.
Methods
This was a prospective, interventional case series of 31
eyes of 31 treatment-naïve patients (20 men and 11
women) with unilateral CRVO. The patients were exam-
ined by LSFG and microperimetry at the baseline and at
1, 3, and 6 months after IVB or IVR for ME due to a
CRVO. The fluorescein arteriovenous passage time was
determined at the baseline. All patients were examined
within 3 month of the onset of the symptoms. The age
of the patients at presentation ranged from 40 to 83 years
(mean, 66.9 years). All treatment-naïve patients who
were diagnosed with ME due to CRVO, had a healthy
fellow eye, and had IVB or IVR injections in the
Department of Ophthalmology of Saneikai Tsukazaki
Hospital from October 2012 through February 2015 were
studied. Approval was obtained from the Institutional
Review Board of Saneikai Tsukazaki Hospital prior to be-
ginning this study, and the patients gave their written
informed consent prior to their inclusion. The patients
have provided permission to publish clinical data of their
case in this study. This study was registered with the
University hospital Medical Information Network
(UMIN) clinical trials registry. The registration title is
“UMIN000009072, Correlation between optic nerve head
circulation and retinal sensitivity before and after anti-
VEGF drug intravitreal injection for central retinal vein oc-
clusion” (October 15, 2012). The procedures used in this
study adhered to the tenets of the Declaration of Helsinki.
Patients with ME due to a CRVO, central foveal thick-
ness of ≥250 μm in the optical coherence tomographic
(OCT) images, and a decimal visual acuity from 0.01 to
0.8 were studied. Patients with a history of cerebral in-
farction, anti-VEGF therapy, vitrectomy, and uveitis, or
other vitreoretinal diseases were excluded. In addition,
patients with uncontrolled high blood pressure, diabetes,
intraocular pressure (IOP) of 21 mmHg or more, or iris
neovascularization were excluded.
The blood flow of the major blood vessels on the
ONH was measured in all patients, and the arterioven-
ous passage time of the retina was determined by fluor-
escein angiography (FA). A previous study investigating
CRVO with FA [14] showed that more than 10 disc
areas of the nonperfusion areas were observed in the
ischemic type of CRVO. Thus, a diagnosis of ischemic
CRVO was made in eyes with more than 10 disc areas of
the nonperfusion areas [11]. The venous tortuosity index
was calculated on color fundus photograph.
Patients who started their treatment between October
2012 and August 2013 received IVB injections (1.25 mg/
0.05 mL), and those who started treatment between
September 2013 and February 2015 received IVR injec-
tions (0.5 mg/0.05 mL). After the initial treatment, the
patients were examined once a month. When the central
foveal thickness was ≥250 μm, or the physician deter-
mined that additional treatment was necessary, the
patients received additional injections of the same anti-
VEGF agent.
All patients had a standard ophthalmologic examination
including IOP measurements before and after IVB or IVR.
The best-corrected visual acuity (BCVA) was measured
with a standard Japanese Landolt visual acuity chart, and
the decimal visual acuity was converted to the logarithm
of the minimal angle of resolution (logMAR) units for stat-
istical analyses. The anterior and posterior segments were
examined by slit-lamp biomicroscopy, indirect ophthal-
moscopy, color fundus photography, and spectral-domain
OCT (SD-OCT). The systolic blood pressure (SBP), dia-
stolic blood pressure (DBP), and heart rate were measured.
The mean arterial pressure (MAP) and the mean ocular
perfusion pressure (MOPP) were calculated according to
the following formulas and used for the analyses: MAP=
DBP+ 1/3 (SBP - DBP), and MOPP= 2/3 MAP – IOP.
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Laser speckle flowgraphy
LSFG-NAVI (Softcare, Fukuoka, Japan) was used to
evaluate the ONH circulation in eyes with a CRVO
(Figs. 1 and 2). The principles of LSFG have been
reported in detail [15]. In brief, LSFG uses a diode laser
(wavelength 830 nm) to detect the movement of the red
blood cells in the blood vessels. The light scattered by the
movement of the blood cells creates speckle patterns on
the area where the sensor is focused, and the scattered light
produces a blur in the speckle patterns. The mean blur
rate, which is the change in the blur, is a quantitative value
that represents the relative blood flow velocity [15–19].
Fig. 1 Ophthalmologic examination images before and 6 months after anti-VEGF therapy for central retinal vein occlusion. Fundus photograph,
spectral-domain optical coherence tomographic (SD-OCT) images, laser speckle flowgraphic (LSFG) images, and microperimetric maps before and
6 months after an initial anti-VEGF therapy of the right eye of a 66-year-old woman with cystoid macular edema (CME) due to a central retinal
vein occlusion are presented. The decimal best-corrected visual acuity was 0.5 before the treatment and 1.0 at 6 months after the treatment.
a: Fundus photograph at the baseline. The venous tortuosity index was calculated on color fundus photograph. Measurements of superior and
inferior venous arcades were obtained starting from the optic disc margin to the crossing point of a circle whose diameter is the distance from
the center of optic disc to the fovea. The course of the veins was traced using Photoshop (Adobe Systems, Inc. Ca, USA). NIH ImageJ software
was used to measure the lengths of the tortuous vein (c and d) and chord of the vessels (a and b). The venous tortuosity was calculated by
dividing the length of the tortuous retinal vein by the chord length of the same segment (c/a and d/b). The average of the venous tortuosity
((c/a + d/b)/2) was calculated to obtain the venous tortuosity index. b: SD-OCT image at the baseline showing CME. c: SD-OCT image at 6 months
showing a resolution of the CME. d: A false-color composite map of the optic nerve head was created using the LSFG findings at the baseline.
The red area indicates a faster blood flow, and the blue area indicates a slower blood flow. e: A false-color composite map by LSFG at 6 months.
There is no obvious difference in the blood flow as compared with the LSFG map at the baseline (d). f: Microperimetric map image at the baseline. A
total of 37 stimulus locations covering the central 10° field were tested. The mean retinal sensitivity at the 37 locations is 19.1 dB. g: Microperimetric
map image at 6 months. The mean retinal sensitivity at the 37 locations is 24.5 dB
Nagasato et al. BMC Ophthalmology  (2016) 16:36 Page 3 of 10
The patient's pupil was dilated with Mydrin P (1 % tropi-
camide and 2.5 % phenylephrine) 30 min prior to the
LSFG examinations. During the examinations, the patients
were instructed to fixate steadily on a target light while
the speckle pattern on the ONH was recorded. With an
auto-tracking system, the same site can be measured for
several seconds. The relative blood flow velocity is repre-
sented by the MBR and displayed as a two-dimensional
color map. The MBR of the vessel area is expressed as the
MV and the MBR of the tissue area as the MT. The
appropriate threshold between the vessel and tissue areas
is automatically determined by the built-in software, and
the MBR of the area of the major arteries and veins as
MV and the MBR of the tissue area as MT can be calcu-
lated (Fig. 3) [9].
When measuring the retinal circulation with LSFG,
the measurements are influenced by the deep choroidal
circulation. Similarly, the ONH measurements are
influenced by the blood flow of the ONH tissue (MT)
[15, 16]. To evaluate the major arteriovenous circulation
Fig. 2 Ophthalmologic examination images before and 6 months after anti-VEGF therapy for central retinal vein occlusion. Fundus photograph,
spectral-domain optical coherence tomographic (SD-OCT) images, laser speckle flowgraphic (LSFG) images, and microperimetric maps before and
6 months after an initial anti-VEGF therapy of the right eye of a 66-year-old man with cystoid macular edema (CME) due to a central retinal vein
occlusion are presented. The decimal best-corrected visual acuity was 0.3 before the treatment and 0.1 at 6 months after the treatment. a: Fundus
photograph at the baseline. Note that the venous tortuosity is larger as compared with fundus photograph presented in Fig. 1a. b: SD-OCT image at
the baseline shows CME. c: SD-OCT image at 6 months indicates residual CME and retinal thinning around the fovea. d: A false-color composite map
at the optic nerve head was created using LSFG at the baseline. The red area indicates a faster blood flow, and the blue area indicates a slower blood
flow. e: A false-color composite map by LSFG at 6 months. Note the decrease of blood flow as compared with the LSFG map before the treatment (d).
f: Microperimetric map at the baseline. The mean retinal sensitivity at the 37 locations is 14.4 dB. g: Microperimetric map image at 6 months. The mean
retinal sensitivity at the 37 locations is 10.6 dB
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of the ONH excluding the blood flow of the ONH tissue,
the value was obtained by subtracting the MT from the
MV [11]. In addition, to exclude the influence of each
patient's systemic circulation at the time of the measure-
ments and to allow for inter-patient comparisons of the
measurements, a corrected MBR value was obtained by
the MBR (MV minus MT) of the affected eye divided by
the MBR (MV minus MT) of the fellow eye [11]. The
LSFG was measured at the baseline and at 1, 3, and
6 months after the initial treatment.
Microperimetry
The retinal sensitivity was determined by macular integ-
rity assessment (MAIA) microperimetry (CenterVue,
Padova, Italy; Figs. 1 and 2). MAIA testing was con-
ducted in a dark room without pupil dilation. The test-
ing conditions were similar to that described in detail in
previous studies [17, 18]. Briefly, 37 loci in the 10° cen-
tral macula was assessed using a 4 to 2 threshold strat-
egy, a fixation target that consisted of a red circle with a
1° diameter, stimulus size of Goldmann III, background
luminance of 4 apostilb (asb), maximum luminance of
1000 asb, and a stimulus dynamic range of 36 dB.
Calculation of venous tortuosity index
The venous tortuosity index was calculated as previously
reported (Figs. 1 and 2) [20, 21]. Briefly, color fundus
photographs were obtained with a Topcon fundus cam-
era (TRC-50DX, Topcon, Tokyo, Japan). The course of
the veins was traced using the Photoshop software
(Adobe Systems, Inc. Ca, USA). Measurements of the
superior and inferior venous arcades were obtained
starting from the ONH margin to the crossing point of a
circle whose diameter was the distance from the center
of ONH to the fovea. NIH ImageJ software was used to
measure the length of the tortuous vein and length of
the chord of the vessel. The venous tortuosity was calcu-
lated by dividing the arc length of the retinal vein by the
chord length of the same segment. The average of the
venous tortuosity of the superior and inferior venous
Fig. 3 Composite maps and histograms at the optic nerve head (ONH) created by laser speckle flowgraphy. a: A false-color composite map at
the ONH. b: A histogramic analysis of the ONH. The vertical axis represents the number of pixels and the horizontal axis represents the mean blur
rate. c: A binary format image for segmentation between the vessel (white area) and tissue (black area) areas. d: A histogram analyzed using the
built-in image viewer software that uses an automated definitive threshold. The area to the left of the threshold line corresponds to the ONH
tissue (black area in c), whereas the area to the right of the line corresponds to the ONH vessel (white area in c)
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arcades was calculated to obtain the venous tortuosity
index.
Statistical analyses
Repeated-measures analysis of variance (ANOVA) with
Greenhouse-Geisser corrections was used to determine
the significance of the changes in the BCVA, retinal sen-
sitivity, corrected MBR, MV, MT, SBP, DBP, heart rate,
IOP, MAP, and MOPP. The Bonferroni test was used for
post hoc analysis. Pearson’s correlation tests were used
to determine the significance of correlations between the
corrected MBR and the BCVA, retinal sensitivity, ar-
teriovenous passage time, or venous tortuosity index. A
P value of <0.05 was considered statistically significant.
Results
All patients were followed for at least 6 months after the
initial injection of IVB or IVR. IVB was performed on 15
eyes and IVR on 16 eyes. The injections were adminis-
tered two to five times (3.52 ± 0.88 (mean ± SD)) to each
patient during the 6 months. According to the FA find-
ings, the diagnosis of nonischemic CRVO was made in
26 eyes (Figs. 4 and 5), and the diagnosis of ischemic
CRVO was made in 5 eyes. The SBP, DBP, heart rate,
IOP, MAP, and MOPP were not significantly different
among the baseline and 1, 3, and 6 months after the
treatments (P = 0.930, P = 0.958, P = 0.966, P = 0.745,
P = 0.969, P = 0.886, respectively).
At the baseline, the corrected MBR was 0.63 ± 0.26.
The arteriovenous passage time on FA was 14.0 ± 5.2 s,
and the venous tortuosity index on color fundus photo-
graph was 1.113 ± 0.053. The corrected MBR was sig-
nificantly correlated with the arteriovenous passage time
(r = -0.807, P <0.001; Fig. 6a) and venous tortuosity
index (r = -0.716, P <0.001). The corrected MBR after
the first intravitreal injection was 0.60 ± 0.23 at 1 month,
0.61 ± 0.23 at 3 months, and 0.62 ± 0.28 at 6 months
(Additional file 1). No significant differences were ob-
served in the corrected MBR among the baseline and
post-treatment times (P = 0.379). The MV in the af-
fected eye was 34.8 ± 11.2 at the baseline, 32.0 ± 10.3 at
1 month, 31.6 ± 10.9 at 3 months, and 32.9 ± 12.2 at
6 months. No significant differences were observed in the
MV among the baseline and post-treatment times (P =
0.116). The MT was 14.3 ± 4.6 at the baseline, 12.4 ± 3.8 at
1 month, 11.7 ± 4.0 at 3 months, and 12.3 ± 4.2 at
6 months. Significant differences were observed in the MT
among the baseline and post-treatment times (P = 0.003).
The MT at 1 and 3 months was significantly smaller than
that at the baseline (P = 0.011, P = 0.002, respectively).
The mean BCVA was 0.68 ± 0.48 logMAR units at the
baseline, 0.39 ± 0.36 logMAR units at 1 month after the
first intravitreal injection, 0.36 ± 0.35 logMAR units at
3 months, and 0.33 ± 0.42 logMAR units at 6 months. Sig-
nificant differences were observed in the BCVA among the
baseline and post-treatment times (P <0.001). The BCVA
at 1, 3, and 6 months was significantly better than that at
the baseline (P <0.001, P = 0.001, P = 0.007, respectively).
The retinal sensitivity was 15.2 ± 7.5 dB at the baseline,
18.7 ± 6.6 dB at 1 month, 20.9 ± 6.0 dB at 3 months, and
20.4 ± 6.0 dB at 6 months. Significant differences were
observed in the retinal sensitivity among the baseline
and post-treatment times (P <0.001). The retinal sensi-
tivity at 1, 3, and 6 months was significantly better than
that at the baseline (P = 0.001, P <0.001, P = 0.001,
respectively).
Fig. 4 Fluorescein angiography before anti-VEGF therapy for central
retinal vein occlusion (CRVO). The same case presented in Fig. 1.
Because there are not more than 10 disc areas of the nonperfusion
areas, this case was diagnosed with nonischemic CRVO
Fig. 5 Fluorescein angiography before anti-VEGF therapy for central
retinal vein occlusion (CRVO). The same case presented in Fig. 2.
Because there are not more than 10 disc areas of the nonperfusion
areas, this case was also diagnosed with nonischemic CRVO
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Fig. 6 (See legend on next page.)
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The MBR was significantly correlated with the BCVA
(all P <0.005) and the retinal sensitivity (all P <0.050,
Table 1) at all time points.
There was a significant correlation between the cor-
rected MBR at the baseline and the BCVA at 6 months
(r = -0.651, P <0.001; Fig. 6b). There was also a signifi-
cant correlation between the corrected MBR at the
baseline and the retinal sensitivity at 6 months (r = 0.485,
P = 0.005; Fig. 6c).
Discussion
The results showed that the corrected MBR at the base-
line was significantly correlated with the BCVA and ret-
inal sensitivity at 6 months after anti-VEGF therapy.
This indicates that the visual prognosis is good in pa-
tients with CRVO who have good blood flow on the
ONH at the baseline. In a report on 3 cases with CRVO,
Matsumoto et al. also suggested that the prognosis of
CRVO may be predicted by measuring the MBR using
LSFG [13]. In eyes with ME due to a BRVO, Nagaoka
et al. reported that the visual prognosis was good when
the retinal blood flow measured by laser Doppler velo-
cimetry before IVB was good [12]. Taken together, these
results suggest that the status of the blood flow prior to
the treatment is a useful predictor of the post-treatment
BCVA for both CRVO and BRVO.
The measurements of the LSFG had excellent repro-
ducibility which then permitted a non-invasive method
to measure the ocular circulation. Aizawa et al. used
LSFG and reported that the intra-session reproducibility
of the MBR in the ONH of three continuous ex-
aminations was excellent with a coefficient of variation
of 3.4 ± 2.0 and an intraclass correlation coefficient of
0.95 [9]. Aizawa et al. also reported that the MBR of the
ONH tissue was strongly correlated with the visual field
sensitivity in eyes with glaucoma [3]. In addition,
Maekubo et al. reported that measurements of the ONH
circulation by LSFG could be used for differentiating
nonarteritic ischemic optic neuropathy from anterior
optic neuritis [19]. Based on these findings, measuring
the ONH circulation by LSFG can be considered a use-
ful method in the clinic.
Yamada et al. measured the MBR on the ONH in eyes
with untreated CRVO [11]. The corrected MBR was cal-
culated to exclude the influence of the systemic circula-
tion and blood flow of the ONH tissue. After obtaining
the MBR values by subtracting the MT from the MV,
the ONH blood flow was evaluated by taking the MBR
values of the affected eye divided by the MBR values of
the healthy fellow eye. The authors reported that this
corrected MBR was significantly correlated with the ar-
teriovenous passage time [11]. Similarly, a significant
correlation was found between the corrected MBR and
arteriovenous passage time in the present study. The
strong correlation between the corrected MBR and
arteriovenous passage time, which has been used as an
indicator of retinal circulation, confirms that the method
we used is a highly reliable way to evaluate the circula-
tory status of the ONH. In addition, Yamada et al. re-
ported that the corrected MBR values in large ONH
vessels were significantly correlated with the aqueous
VEGF concentrations in eyes with CRVO [11].
It is sometimes difficult to distinguish the vessel and
tissue areas at the ONH in eyes with CRVO, because
dilatation or blood stasis of capillary vessel on ONH ob-
scures the boundary between the large vessel and tissue
(See figure on previous page.)
Fig. 6 Correlation between optic nerve head (ONH) circulation and arteriovenous passage time or visual function. Correlation between the
baseline mean blur rate (MBR) at the ONH and the baseline arteriovenous passage time, the best-corrected visual acuity (BCVA) at 6 months, or
mean retinal sensitivity at 6 months is presented. To exclude the influence of systemic circulation and blood flow of ONH tissue, the corrected
MBR was calculated as; (MBR of ONH vessel area – MBR of ONH tissue area) in the affected eye ÷ (vascular MBR – tissue MBR) in the healthy
fellow eye [11]. a: Correlation between the baseline corrected MBR at the ONH and the arteriovenous passage time at the baseline. The corrected MBR
is significantly correlated with the arteriovenous passage time on fluorescein angiography (r = -0.807, P <0.001). The solid line represents the linear
regression line (y = -16.102x + 24.200). b: Correlation between the baseline corrected MBR at the ONH and BCVA in logMAR units at 6 months after the
initial treatment. The corrected MBR is significantly correlated with the BCVA at 6 months (r = -0.651, P <0.001). The solid line represents the linear
regression line (y = -1.036x + 0.983). c: Correlation between the baseline corrected MBR at the ONH and mean retinal sensitivity at 6 months. The
corrected MBR is significantly correlated with the retinal sensitivity at 6 months (r = 0.485, P = 0.005). The solid line represents the linear regression
line (y = 11.059x + 13.378)
Table 1 Correlations between MBR on ONH and BCVA or retinal
sensitivity before and after anti-VEGF therapy
Corrected MBR on ONH
Baseline 1 month 3 months 6 months
BCVA (logMAR) r = -0.543 r = -0.672 r = -0.546 r = -0.565
P = 0.001 P < 0.001 P = 0.001 P <0.001
Retinal sensitivity (dB) r = 0.572 r = 0.608 r = 0.552 r = 0.430
P <0.001 P <0.001 P = 0.001 P = 0.015
BCVA, best corrected visual acuity; Corrected MBR, (MBR of ONH vessel area – MBR
of ONH tissue area) in the affected eye ÷ (vascular MBR – tissue MBR) in the
unaffected eye; logMAR, logarithm of the minimum angle of resolution; MBR,
mean blur rate; ONH, optic nerve head; VEGF, vascular endothelial growth factor
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on the LSFG images. Thus, the MV and MT values mea-
sured in eyes with CRVO may include a measurement
error. However, the corrected MBR in the present study
was significantly correlated with not only arteriovenous
passage time on FA but also the venous tortuosity index
on fundus photograph, which suggests that this meas-
urement error is considered to be small.
Nitta et al. reported that there was no significant
change in the MBR measured by LSFG in the retinal
artery, retinal vein, or ONH after a single IVB injection
in eyes with a BRVO [22]. Nagaoka et al. also reported
no significant changes in the retinal blood flow mea-
sured by laser Doppler velocimetry after a single IVB
injection for BRVO [12]. Consistent with these findings,
our results showed no significant differences in the cor-
rected MBR after IVB or IVR in eyes with a CRVO. On
the other hand, Matsumoto et al. reported 3 cases of
ME secondary to nonischemic CRVO in which the
blood flow increased after IVBs [13]. In their case, the
MBR increased in 3 or 4 weeks after the IVB was con-
firmed by LSFG, but long term changes of the MBR
and exact relationship between the MBR and visual
prognosis were unclear.
This study has several limitations. First, the sample
size was small, and the follow-up period was short. Fur-
ther studies with a larger sample size and longer
follow-up periods would be required to confirm our
findings. We also need to keep in mind that when using
LSFG the MBR is a relative value of the blood flow vel-
ocity and not the absolute value. Therefore, when com-
paring the difference between eyes, we used the
corrected MBR value. The other limitation is that the
present study included both patients treated with IVB
and those with IVR. Lastly, Mayama et al. reported that
phenylephrine eye drops can depress the ONH circula-
tion [23]. In our study, Mydrin P, tropicamide and
phenylephrine, was used prior to the LSFG testing to
obtain more accurate measurements of the ONH circu-
lation with LSFG. Thus, there is a possibility that
phenylephrine may have influenced the ONH circula-
tion. However, because Mydrin P was administered to
both the affected and unaffected eyes and ONH circula-
tion was evaluated using the equation; the MBR of the
affected eye/MBR of the unaffected eye, the magnitude
of this influence may be small.
Conclusions
The blood flow velocity on the ONH was significantly
correlated with the BCVA and retinal sensitivity before
and after anti-VEGF therapy for CRVO. We suggest that
the blood flow velocity of the ONH before the therapy is
a predictive factor for the visual outcome after treatment
for CRVO.
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